Treatment Algorithms for Managing Hepatocellular Carcinoma

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue , 2014, Pages S80-S89

  Saraswat, Vivek A ^a   Pandey, Gaurav ^a   Shetty, Sachin ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

BCLC; Liver cancer; staging; treatment algorithm

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CHEMOEMBOLIZATION; CHRONIC HEPATITIS B; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; MANAGED CARE; PATIENT CARE; PATIENT CODING; PORTAL HYPERTENSION; PRIORITY JOURNAL; REOPERATION; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR ABLATION;

EID: 84940105575     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.05.004     Document Type: Review

References (47)

1. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751-755.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
3. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918-928.
4. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
5. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2010.
6. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol. 1999;31:133-141.
7. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760-1769.
8. Nanashima A, Sumida Y, Morino S, et al. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 2004;30:765-770.
9. Kitai S, Kudo M, Minami Y, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncol. 2008;75:S83-S90.
10. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329- 338.
11. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
12. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. http://dx.doi.org/10.1200/JCO.2010.28.7805. Epub 2010 Aug 2.
13. Bruix J, Sherman M, American Association for Study of Liver Diseases. Hepatology. 2011;53:1020-1022. http://dx.doi.org/10. 1002/hep.24199.
14. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716.
15. Hohida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010;30:35-51.
16. Clavien PA, Lesurtel M, Bossuyt PM, et al. OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-22. http://dx.doi.org/10.1016/S1470- 2045(11)70175-9. Epub 2011 Oct 31.
17. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998;28:1241-1246.
18. Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850-855.
19. Roayaie S, Llovet JM, Obeidat K, et al. Hepatic resection for hepatocellular carcinoma <2 cm in diameter. Hepatology. 2013;57:1426-1435.
20. Livraghi T, Meloi F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82-89.
21. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
22. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92:205-216.
24. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
25. Vennarecci G, Ettorre GM, Antonini M, et al. First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis. Transplant Proc. 2007;39:1857-1860.
26. Verslype C, Rosmorduc O, Rougier P, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii41-vii48. http://dx.doi.org/10.1093/annonc/ mds225.
27. Kakodkar R, Soin AS. Liver transplantation for HCC: a review. Indian J Surg. 2012;74:100-117.
28. Belghiti J, Durand F. Hepatectomy vs. liver transplantation: a combination rather than an opposition. Liver Transpl. 2007;13:636- 638. http://dx.doi.org/10.1002/lt.21023.
29. Del Gaudio M, Ercolani G, Ravaioli M, et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transpl. 2008;8:1177-1185.
30. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC Guidelines. J Gastroenterol. 2009;44:119-121. http://dx.doi.org/10.1077/ s00535-008-2244-z.
31. Kudo M, Izumi N, Kokudo N, HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339-364. http://dx.doi.org/10.1159/000327577.
32. Chen GH, Fu BS, Yang Y, et al. Early liver retransplantation versus late liver retransplantation: analysis of a single-centre experience. Chin Med J Engl. 2008;121:1992-1996.
33. Zhou Y, Sui C, Li B, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J Surg Oncol. 2010;8:55. http://dx.doi.org/10.1186/ 1477-7819-8-55.
34. Arii S, Monden K, Niwano M, et al. Results of surgical treatment for recurrent hepatocellular carcinoma: comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg. 1998;5:86-92.
35. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328.
36. Camma C, Di Marco V, Orlando A, et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radiofrequency thermal ablation (RFTA): a prospective study. J Hepatol. 2005;42:535- 540.
37. Yang W, Chen MH, Yin SS, et al. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence. AJR Am J Roentgenol. 2006;186:S275-S283.
38. Liang X, Cai XJ, Yu H, Wang YF, Liang YL. Second laparoscopic resection for recurrent hepatocellular carcinoma after initial laparoscopic hepatectomy: case report. Chin Med J Engl. 2009;122:1359-1360.
39. Llovet JM, Vilana R, Brú C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33:1124-1129.
40. Boucher E, Corbinais S, Rolland Y, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology. 2003;38:1237-1241.
41. Shim JH, Park JW, Choi JI, et al. Does post-embolization fever after chemo-embolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol. 2009;20:209-216.
42. Choi JW, Park JY, Ahn SH, et al. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. Am J Clin Oncol. 2009;32:564-569. http://dx.doi.org/10.1097/COC. 0b013e3181967da0.
43. Charing Ching Ning Chong and Paul Bo San Lai. Treatment strategy for recurrent hepatocellular carcinoma. www.intechopen.com/ download/pdf/27581.
44. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. http://dx.doi.org/10.1016/ S1470-2045(08)70285-7. Epub 2008 Dec 16.
45. Chua TC, Morris DL. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol. 2012;21:95-101. http://dx.doi.org/10.1016/j.suronc.2011.01.Epub 2011 Mar 11.
46. Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33:1104-1112. http:// dx.doi.org/10.1111/j.1365-2036.2011.04634.x. Epub 2011 Mar 24.
47. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131- labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial update on 5-year and 10-year survival. Ann Surg. 2008;247:43-48.